

## 12 THE EXPRESSION OF SPLICE FORMS FOR THE RHEUMATOID ARTHRITIS RISK ASSOCIATED GENE PTPN22 IS SIGNIFICANTLY DIFFERENT FOR PATIENTS COMPARED TO CONTROLS

Marcus Ronninger,<sup>1</sup> Yongjing Guo,<sup>2</sup> Klementy Shchetynsky,<sup>1</sup> Andrew Hill,<sup>4</sup> Mohsen Khademi,<sup>3</sup> Tomas Olsson,<sup>3</sup> Padmalatha S Reddy,<sup>4</sup> Maria Seddighzadeh,<sup>1</sup> James D Clark,<sup>2</sup> Lih-Ling Lin,<sup>2</sup> Margot O'Toole,<sup>2</sup> Leonid Padyukov<sup>1</sup> <sup>1</sup>Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden; <sup>2</sup>Inflammation and Immunology, Pfizer Research, 200 CambridgePark Drive, Cambridge, UK; <sup>3</sup>Department of Clinical Neurosciences, Division of Neuroimmunology, Karolinska Institute, Stockholm, Sweden

10.1136/annrheumdis-2011-201236.12

**Background** Several genetic risk factors have been revealed for rheumatoid arthritis (RA) whereof *HLA-DRB1* shared epitope alleles and *PTPN22* remains the two most undisputed for the disease. Hypotheses for how these associations confer their risk exist but the etiology is still not completely explained. The *PTPN22* risk allele is associated with a gain of function of the protein product. However, the *PTPN22* gene has alternatively spliced transcripts where at least two of the splice forms have confirmed different *PTPN22* (LYP) proteins, which may influence the proteins pathways.

**Objectives** Our hypothesis was that *PTPN22* splice forms may have a different expression pattern in patients compared to controls. Such an effect could enhance other effects from the associated risk alleles.

**Material and methods** The authors have investigated the expression of *PTPN22* splice forms in peripheral blood cells and used genotypic and phenotypic data for analysis of RA patients and controls of Caucasian origin.

**Results** *PTPN22* was found to be different in individuals with RA compared to controls. On average, the shorter splice form was reduced (0.8-fold,  $p=0.08$ ) and the longer was increased (1.2-fold,  $p=0.006$ ) for patients. This effect was further enhanced if the ratio of the transcripts for each individual was compared (1.4-fold,  $p=6 \times 10^{-9}$ ). This finding was replicated in two independent cohorts of the total size of 165 individuals.

**Conclusions** The authors found important differences in expression of *PTPN22* splice forms between healthy individuals and RA patients, which may increase a gain of function that influence development of the disease. The balance between splice forms may also be of importance during immune response due to great structural differences in the encoded *PTPN22* proteins.